The effect of six-month oral vitamin K supplementation on calcification propensity time in individuals with type 2 diabetes mellitus: A post hoc analysis of a randomized, double-blind, placebo-controlled trial
Experimental studies suggested that vitamin K supplementation may retard arterial calcification. Recently, serum calcification propensity time (T50) has been suggested as a functional biomarker for arterial wall calcification propensity. In this post-hoc analysis of a clinical trial, we evaluated th...
Gespeichert in:
| Veröffentlicht in: | Atherosclerosis 2024-07, Vol.394, p.117307, Article 117307 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 117307 |
| container_title | Atherosclerosis |
| container_volume | 394 |
| creator | Meer, R. Romero Prats, M.L. Vervloet, M.G. van der Schouw, Y.T. de Jong, P.A. Beulens, J.W.J. |
| description | Experimental studies suggested that vitamin K supplementation may retard arterial calcification. Recently, serum calcification propensity time (T50) has been suggested as a functional biomarker for arterial wall calcification propensity. In this post-hoc analysis of a clinical trial, we evaluated the effect of six-month oral vitamin K supplementation on T50 and assessed the correlation between T50 and imaging arterial calcification parameters in people with type 2 diabetes (T2DM).
This double-blind, randomized, placebo-controlled trial included 68 participants (age = 69 ± 8 years, 76% male) with T2DM. Participants were assigned to menaquinone-7 (360 μg/day; n = 35) or placebo (n = 33). T50 was measured via nephelometry in serum collected at baseline, three and six months. Arterial calcification was measured at baseline and six months via 18F–Na PET-CT and conventional CT using Target-to-Background ratio (TBR) and Agatston score. Longitudinal analysis of covariance adjusted for baseline T50 was used to study the treatment effect. Spearman's correlation was used to assess the correlation between T50 and imaging calcification parameters.
Median baseline T50 was similar in the vitamin K (350 [321–394] minutes) and placebo groups (363 [320–398]). There was no significant difference in T50 between treatment arms over time (ẞ = 1.00, 95%C.I. = 0.94–1.07, p = 0.982). The correlation coefficient of T50 with TBR and Agatston score at baseline were −0.185 (p = 0.156) and −0.121 (p = 0.358), respectively.
No effect of vitamin K supplementation on T50 was observed in T2DM. Moreover, T50 did not correlate with TBR and Agatston score. Further research on vitamin K in arterial calcification and on the validity of T50 as arterial calcification marker is warranted.
[Display omitted]
•Vitamin K did not improve serum calcification propensity time in type 2 diabetes.•Serum calcium propensity time did not correlate with PET-CT and CT parameters.•Further research on the role of vitamin K in arterial calcification is warranted.•New research on the validity of T50 as measure of arterial calcification is needed. |
| doi_str_mv | 10.1016/j.atherosclerosis.2023.117307 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2879405623</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0021915023052280</els_id><sourcerecordid>2879405623</sourcerecordid><originalsourceid>FETCH-LOGICAL-c389t-70212b525cc498dc1bc15e7ffc04249654fea5cfccb2be654609a73b5ff354823</originalsourceid><addsrcrecordid>eNqNkcFu1DAQhiMEokvhFdBckDg0i-0kmwSJQ1VBQVTiUs6WY4-1s3LiYDsLy1vyRniVwoETkmXL1j__zO-vKF5xtuWM794ctirtMfio3XmnuBVMVFvO24q1j4oN79q-5HVXPy42jAle9rxhF8WzGA-Msbrl3dPiomq7RnS7blP8ut8joLWoE3gLkX6Uo5_SHnxQDo6U1EgTfIa4zLPDEaekEvkJ8tLKabKk14c5-BmnSOkEiUaEXEWToSOZRbkI3yl7ptOMIMCQGjBhhBGdo7TEt3ANs48J9l6DmpQ75VzncRQENRk_0k80V2D8MjgsB5eNr2B2SuPgS53HDd45NJACKfe8eGJzR3zxcF4WXz-8v7_5WN59uf10c31X6qrrU9nmvxFDIxqt674zmg-aN9haq1kt6n7X1BZVo63WgxgwX3esV201NNZWTd2J6rJ4vfrm5N8WjEmOFHVOpCb0S5Qig6hZsxNVlr5bpToTiwGtnAONKpwkZ_JMVR7kP1Tlmapcqeb6lw-tlmFE87f6D8YsuF0FmAMfCYOMmnDSaChkstJ4-s9WvwEy38L2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2879405623</pqid></control><display><type>article</type><title>The effect of six-month oral vitamin K supplementation on calcification propensity time in individuals with type 2 diabetes mellitus: A post hoc analysis of a randomized, double-blind, placebo-controlled trial</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Meer, R. ; Romero Prats, M.L. ; Vervloet, M.G. ; van der Schouw, Y.T. ; de Jong, P.A. ; Beulens, J.W.J.</creator><creatorcontrib>Meer, R. ; Romero Prats, M.L. ; Vervloet, M.G. ; van der Schouw, Y.T. ; de Jong, P.A. ; Beulens, J.W.J.</creatorcontrib><description>Experimental studies suggested that vitamin K supplementation may retard arterial calcification. Recently, serum calcification propensity time (T50) has been suggested as a functional biomarker for arterial wall calcification propensity. In this post-hoc analysis of a clinical trial, we evaluated the effect of six-month oral vitamin K supplementation on T50 and assessed the correlation between T50 and imaging arterial calcification parameters in people with type 2 diabetes (T2DM).
This double-blind, randomized, placebo-controlled trial included 68 participants (age = 69 ± 8 years, 76% male) with T2DM. Participants were assigned to menaquinone-7 (360 μg/day; n = 35) or placebo (n = 33). T50 was measured via nephelometry in serum collected at baseline, three and six months. Arterial calcification was measured at baseline and six months via 18F–Na PET-CT and conventional CT using Target-to-Background ratio (TBR) and Agatston score. Longitudinal analysis of covariance adjusted for baseline T50 was used to study the treatment effect. Spearman's correlation was used to assess the correlation between T50 and imaging calcification parameters.
Median baseline T50 was similar in the vitamin K (350 [321–394] minutes) and placebo groups (363 [320–398]). There was no significant difference in T50 between treatment arms over time (ẞ = 1.00, 95%C.I. = 0.94–1.07, p = 0.982). The correlation coefficient of T50 with TBR and Agatston score at baseline were −0.185 (p = 0.156) and −0.121 (p = 0.358), respectively.
No effect of vitamin K supplementation on T50 was observed in T2DM. Moreover, T50 did not correlate with TBR and Agatston score. Further research on vitamin K in arterial calcification and on the validity of T50 as arterial calcification marker is warranted.
[Display omitted]
•Vitamin K did not improve serum calcification propensity time in type 2 diabetes.•Serum calcium propensity time did not correlate with PET-CT and CT parameters.•Further research on the role of vitamin K in arterial calcification is warranted.•New research on the validity of T50 as measure of arterial calcification is needed.</description><identifier>ISSN: 0021-9150</identifier><identifier>ISSN: 1879-1484</identifier><identifier>EISSN: 1879-1484</identifier><identifier>DOI: 10.1016/j.atherosclerosis.2023.117307</identifier><identifier>PMID: 37852868</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Administration, Oral ; Aged ; Arterial calcification ; Biomarkers - blood ; Cardiovascular disease ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - diagnosis ; Diabetes Mellitus, Type 2 - drug therapy ; Dietary Supplements ; Double-Blind Method ; Female ; Humans ; Male ; Middle Aged ; Positron Emission Tomography Computed Tomography ; Randomized controlled trial ; Serum calcification propensity ; Time Factors ; Treatment Outcome ; Type 2 diabetes mellitus ; Vascular Calcification - blood ; Vascular Calcification - diagnostic imaging ; Vascular Calcification - drug therapy ; Vascular Calcification - prevention & control ; Vitamin K ; Vitamin K 2 - administration & dosage ; Vitamin K 2 - analogs & derivatives ; Vitamin K 2 - therapeutic use</subject><ispartof>Atherosclerosis, 2024-07, Vol.394, p.117307, Article 117307</ispartof><rights>2023 The Authors</rights><rights>Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c389t-70212b525cc498dc1bc15e7ffc04249654fea5cfccb2be654609a73b5ff354823</citedby><cites>FETCH-LOGICAL-c389t-70212b525cc498dc1bc15e7ffc04249654fea5cfccb2be654609a73b5ff354823</cites><orcidid>0000-0002-4924-4458</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0021915023052280$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37852868$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Meer, R.</creatorcontrib><creatorcontrib>Romero Prats, M.L.</creatorcontrib><creatorcontrib>Vervloet, M.G.</creatorcontrib><creatorcontrib>van der Schouw, Y.T.</creatorcontrib><creatorcontrib>de Jong, P.A.</creatorcontrib><creatorcontrib>Beulens, J.W.J.</creatorcontrib><title>The effect of six-month oral vitamin K supplementation on calcification propensity time in individuals with type 2 diabetes mellitus: A post hoc analysis of a randomized, double-blind, placebo-controlled trial</title><title>Atherosclerosis</title><addtitle>Atherosclerosis</addtitle><description>Experimental studies suggested that vitamin K supplementation may retard arterial calcification. Recently, serum calcification propensity time (T50) has been suggested as a functional biomarker for arterial wall calcification propensity. In this post-hoc analysis of a clinical trial, we evaluated the effect of six-month oral vitamin K supplementation on T50 and assessed the correlation between T50 and imaging arterial calcification parameters in people with type 2 diabetes (T2DM).
This double-blind, randomized, placebo-controlled trial included 68 participants (age = 69 ± 8 years, 76% male) with T2DM. Participants were assigned to menaquinone-7 (360 μg/day; n = 35) or placebo (n = 33). T50 was measured via nephelometry in serum collected at baseline, three and six months. Arterial calcification was measured at baseline and six months via 18F–Na PET-CT and conventional CT using Target-to-Background ratio (TBR) and Agatston score. Longitudinal analysis of covariance adjusted for baseline T50 was used to study the treatment effect. Spearman's correlation was used to assess the correlation between T50 and imaging calcification parameters.
Median baseline T50 was similar in the vitamin K (350 [321–394] minutes) and placebo groups (363 [320–398]). There was no significant difference in T50 between treatment arms over time (ẞ = 1.00, 95%C.I. = 0.94–1.07, p = 0.982). The correlation coefficient of T50 with TBR and Agatston score at baseline were −0.185 (p = 0.156) and −0.121 (p = 0.358), respectively.
No effect of vitamin K supplementation on T50 was observed in T2DM. Moreover, T50 did not correlate with TBR and Agatston score. Further research on vitamin K in arterial calcification and on the validity of T50 as arterial calcification marker is warranted.
[Display omitted]
•Vitamin K did not improve serum calcification propensity time in type 2 diabetes.•Serum calcium propensity time did not correlate with PET-CT and CT parameters.•Further research on the role of vitamin K in arterial calcification is warranted.•New research on the validity of T50 as measure of arterial calcification is needed.</description><subject>Administration, Oral</subject><subject>Aged</subject><subject>Arterial calcification</subject><subject>Biomarkers - blood</subject><subject>Cardiovascular disease</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - diagnosis</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Dietary Supplements</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Positron Emission Tomography Computed Tomography</subject><subject>Randomized controlled trial</subject><subject>Serum calcification propensity</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Type 2 diabetes mellitus</subject><subject>Vascular Calcification - blood</subject><subject>Vascular Calcification - diagnostic imaging</subject><subject>Vascular Calcification - drug therapy</subject><subject>Vascular Calcification - prevention & control</subject><subject>Vitamin K</subject><subject>Vitamin K 2 - administration & dosage</subject><subject>Vitamin K 2 - analogs & derivatives</subject><subject>Vitamin K 2 - therapeutic use</subject><issn>0021-9150</issn><issn>1879-1484</issn><issn>1879-1484</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkcFu1DAQhiMEokvhFdBckDg0i-0kmwSJQ1VBQVTiUs6WY4-1s3LiYDsLy1vyRniVwoETkmXL1j__zO-vKF5xtuWM794ctirtMfio3XmnuBVMVFvO24q1j4oN79q-5HVXPy42jAle9rxhF8WzGA-Msbrl3dPiomq7RnS7blP8ut8joLWoE3gLkX6Uo5_SHnxQDo6U1EgTfIa4zLPDEaekEvkJ8tLKabKk14c5-BmnSOkEiUaEXEWToSOZRbkI3yl7ptOMIMCQGjBhhBGdo7TEt3ANs48J9l6DmpQ75VzncRQENRk_0k80V2D8MjgsB5eNr2B2SuPgS53HDd45NJACKfe8eGJzR3zxcF4WXz-8v7_5WN59uf10c31X6qrrU9nmvxFDIxqt674zmg-aN9haq1kt6n7X1BZVo63WgxgwX3esV201NNZWTd2J6rJ4vfrm5N8WjEmOFHVOpCb0S5Qig6hZsxNVlr5bpToTiwGtnAONKpwkZ_JMVR7kP1Tlmapcqeb6lw-tlmFE87f6D8YsuF0FmAMfCYOMmnDSaChkstJ4-s9WvwEy38L2</recordid><startdate>202407</startdate><enddate>202407</enddate><creator>Meer, R.</creator><creator>Romero Prats, M.L.</creator><creator>Vervloet, M.G.</creator><creator>van der Schouw, Y.T.</creator><creator>de Jong, P.A.</creator><creator>Beulens, J.W.J.</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4924-4458</orcidid></search><sort><creationdate>202407</creationdate><title>The effect of six-month oral vitamin K supplementation on calcification propensity time in individuals with type 2 diabetes mellitus: A post hoc analysis of a randomized, double-blind, placebo-controlled trial</title><author>Meer, R. ; Romero Prats, M.L. ; Vervloet, M.G. ; van der Schouw, Y.T. ; de Jong, P.A. ; Beulens, J.W.J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c389t-70212b525cc498dc1bc15e7ffc04249654fea5cfccb2be654609a73b5ff354823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Administration, Oral</topic><topic>Aged</topic><topic>Arterial calcification</topic><topic>Biomarkers - blood</topic><topic>Cardiovascular disease</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - diagnosis</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Dietary Supplements</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Positron Emission Tomography Computed Tomography</topic><topic>Randomized controlled trial</topic><topic>Serum calcification propensity</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Type 2 diabetes mellitus</topic><topic>Vascular Calcification - blood</topic><topic>Vascular Calcification - diagnostic imaging</topic><topic>Vascular Calcification - drug therapy</topic><topic>Vascular Calcification - prevention & control</topic><topic>Vitamin K</topic><topic>Vitamin K 2 - administration & dosage</topic><topic>Vitamin K 2 - analogs & derivatives</topic><topic>Vitamin K 2 - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Meer, R.</creatorcontrib><creatorcontrib>Romero Prats, M.L.</creatorcontrib><creatorcontrib>Vervloet, M.G.</creatorcontrib><creatorcontrib>van der Schouw, Y.T.</creatorcontrib><creatorcontrib>de Jong, P.A.</creatorcontrib><creatorcontrib>Beulens, J.W.J.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Atherosclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Meer, R.</au><au>Romero Prats, M.L.</au><au>Vervloet, M.G.</au><au>van der Schouw, Y.T.</au><au>de Jong, P.A.</au><au>Beulens, J.W.J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of six-month oral vitamin K supplementation on calcification propensity time in individuals with type 2 diabetes mellitus: A post hoc analysis of a randomized, double-blind, placebo-controlled trial</atitle><jtitle>Atherosclerosis</jtitle><addtitle>Atherosclerosis</addtitle><date>2024-07</date><risdate>2024</risdate><volume>394</volume><spage>117307</spage><pages>117307-</pages><artnum>117307</artnum><issn>0021-9150</issn><issn>1879-1484</issn><eissn>1879-1484</eissn><abstract>Experimental studies suggested that vitamin K supplementation may retard arterial calcification. Recently, serum calcification propensity time (T50) has been suggested as a functional biomarker for arterial wall calcification propensity. In this post-hoc analysis of a clinical trial, we evaluated the effect of six-month oral vitamin K supplementation on T50 and assessed the correlation between T50 and imaging arterial calcification parameters in people with type 2 diabetes (T2DM).
This double-blind, randomized, placebo-controlled trial included 68 participants (age = 69 ± 8 years, 76% male) with T2DM. Participants were assigned to menaquinone-7 (360 μg/day; n = 35) or placebo (n = 33). T50 was measured via nephelometry in serum collected at baseline, three and six months. Arterial calcification was measured at baseline and six months via 18F–Na PET-CT and conventional CT using Target-to-Background ratio (TBR) and Agatston score. Longitudinal analysis of covariance adjusted for baseline T50 was used to study the treatment effect. Spearman's correlation was used to assess the correlation between T50 and imaging calcification parameters.
Median baseline T50 was similar in the vitamin K (350 [321–394] minutes) and placebo groups (363 [320–398]). There was no significant difference in T50 between treatment arms over time (ẞ = 1.00, 95%C.I. = 0.94–1.07, p = 0.982). The correlation coefficient of T50 with TBR and Agatston score at baseline were −0.185 (p = 0.156) and −0.121 (p = 0.358), respectively.
No effect of vitamin K supplementation on T50 was observed in T2DM. Moreover, T50 did not correlate with TBR and Agatston score. Further research on vitamin K in arterial calcification and on the validity of T50 as arterial calcification marker is warranted.
[Display omitted]
•Vitamin K did not improve serum calcification propensity time in type 2 diabetes.•Serum calcium propensity time did not correlate with PET-CT and CT parameters.•Further research on the role of vitamin K in arterial calcification is warranted.•New research on the validity of T50 as measure of arterial calcification is needed.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>37852868</pmid><doi>10.1016/j.atherosclerosis.2023.117307</doi><orcidid>https://orcid.org/0000-0002-4924-4458</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0021-9150 |
| ispartof | Atherosclerosis, 2024-07, Vol.394, p.117307, Article 117307 |
| issn | 0021-9150 1879-1484 1879-1484 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2879405623 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Administration, Oral Aged Arterial calcification Biomarkers - blood Cardiovascular disease Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Dietary Supplements Double-Blind Method Female Humans Male Middle Aged Positron Emission Tomography Computed Tomography Randomized controlled trial Serum calcification propensity Time Factors Treatment Outcome Type 2 diabetes mellitus Vascular Calcification - blood Vascular Calcification - diagnostic imaging Vascular Calcification - drug therapy Vascular Calcification - prevention & control Vitamin K Vitamin K 2 - administration & dosage Vitamin K 2 - analogs & derivatives Vitamin K 2 - therapeutic use |
| title | The effect of six-month oral vitamin K supplementation on calcification propensity time in individuals with type 2 diabetes mellitus: A post hoc analysis of a randomized, double-blind, placebo-controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T22%3A22%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20six-month%20oral%20vitamin%20K%20supplementation%20on%20calcification%20propensity%20time%20in%20individuals%20with%20type%202%20diabetes%20mellitus:%20A%20post%20hoc%20analysis%20of%20a%20randomized,%20double-blind,%20placebo-controlled%20trial&rft.jtitle=Atherosclerosis&rft.au=Meer,%20R.&rft.date=2024-07&rft.volume=394&rft.spage=117307&rft.pages=117307-&rft.artnum=117307&rft.issn=0021-9150&rft.eissn=1879-1484&rft_id=info:doi/10.1016/j.atherosclerosis.2023.117307&rft_dat=%3Cproquest_cross%3E2879405623%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2879405623&rft_id=info:pmid/37852868&rft_els_id=S0021915023052280&rfr_iscdi=true |